Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease

Stopped The study was stopped due to a higher than expected screen fail rate (83%) which lead to very low patient enrollment into the study. It should be noted that the decision to terminate the study is not related to safety concerns.

Conditions

• Hyperkalaemia
• Metabolic Acidosis
• Chronic Kidney Disease

Interventions

• DRUG: Sodium zirconium cyclosilicate
• DRUG: Placebo

Sponsor

AstraZeneca